Personalis (PSNL) was surging early in Thursday's regular trading session, climbing almost 26%, after the cancer genomic testing and analytics company disclosed a $50 million investment from Merck (MRK) and a multiyear extension agreement with Moderna (MRNA).
Merck will buy around 14 million Personalis shares at $3.56 apiece, matching Wednesday's closing price and providing Merck with roughly 16.5% of the company's outstanding stock, Personalis said.
Personalis said it also extended its collaboration with Moderna to use the company's ImmunoID NeXT tumor-profiling platform to assist with the testing of V940/mRNA-4157 individualized neoantigen therapy being developed jointly by Moderna and Merck. Financial details of the extended agreement weren't provided.
Price: 4.47, Change: +0.91, Percent Change: +25.56
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。